胆固醇
ABCA1
神经突
药理学
药品
药物重新定位
生物合成
流出
下调和上调
细胞内
作用机理
生物
细胞生物学
化学
生物化学
基因
运输机
体外
作者
Srisaiyini Kidnapillai,Chiara C. Bortolasci,Bruna Panizzutti,Briana Spolding,Timothy Connor,Kamila Landucci Bonifácio,Andrew Sanigorski,Olivia M Dean,Tamsyn M. Crowley,Stéphane Jamain,Alastair Gray,Marion Leboyer,Michael Berk,Ken Walder
标识
DOI:10.1080/15622975.2019.1669823
摘要
Objectives: To understand the therapeutic mechanisms of bipolar disorder (BD) drugs at molecular and cellular levels.Methods: Next generation sequencing was used to determine the transcriptional effects of a combination of four commonly prescribed BD drugs (lithium, valproate, lamotrigine and quetiapine) or vehicle (0.2% DMSO) in NT2-N (human neuronal) cells and rats. Differential expression of genes and pathway analysis were performed using edgeR in R and Gene Set Enrichment Analysis software respectively. Free cholesterol levels and neurite outgrowth were quantified in NT2-N cells following combination and individual BD drug treatments.Results: Pathway analysis showed up-regulation of many elements of the cholesterol biosynthesis pathway in NT2-N cells and oxidative phosphorylation in rat brains. Intracellular cholesterol transport genes were upregulated (NPC1, NPC2 and APOE), while the cholesterol efflux gene (ABCA1) was downregulated. BD drug combination tended to increase intracellular cholesterol levels and neurite outgrowth, but these effects were not seen for the drugs when used individually.Conclusions: These data suggest that BD drug combination is increasing cholesterol biosynthesis and the newly synthesised cholesterol is being utilised within the cells, possibly for synthesis of new membranes to facilitate neurite outgrowth. This mechanism possibly underpins clinical efficacy in individuals with BD treated with polypharmacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI